ArticleJournal of translational medicine2025
Hsa_circ_0016662 acts as a prognostic biomarker and promotes the progression of hepatocellular carcinoma via autophagy regulation.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a leading cause of tumour-related death with late diagnoses and high recurrences. Circular RNA (circRNA) plays crucial roles in human malignancies. However, despite the potential as therapeutic target, the role of circRNA and their regulatory network in hepatocellular carcinoma (HCC) remains unclear.
methodsComprehensive bioinformatics approaches were utilized to systematically identify differentially expressed circRNAs (DEcircRNAs) from multiple databases. The ceRNA regulatory network was constructed and the prognostic analysis was performed to screen out hub genes. Pan-cancer, bulk tissue RNA-sequences and single-cell sequences analysis were applied to explore the genetic characteristics and immune landscape of hub genes. By a series of functional assays, the effect of hub circRNA on HCC proliferation, migration and autophagy was assayed both in vitro and in vivo. Dual luciferase reporter and rescue assay were performed for the mechanistic study.
resultsA total of 36 DEcircRNAs were identified and 20 of them were predicted binding with miRNAs binding sites potentially. After establishing the ceRNA regulatory network, functional enrichment, PPI network and prognostic analysis, YWHAZ was discovered as a hub gene in HCC and the subnetwork of hsa_circ_0016662/hsa-miR-22-3p/YWHAZ was recognized. Pan-cancer analysis revealed that YWHAZ was overexpressed and correlated with poor prognosis in most cancers with a 15% frequency of genetic alterations. Multiomics analysis from bulk RNA-sequencing and single-cell RNA-sequencing showed that YWHAZ was a preferable diagnostic and prognostic biomarker in HCC. YWHAZ was associated with suppressive immune microenvironment via positively correlated with the enrichment of macrophages and Tregs, as well as the immunosuppression genes. Real-word cohort validated that hsa_circ_0016662 and YWHAZ were upregulated in HCC while hsa-miR-22-3p was downregulated. Knockdown of hsa_circ_0016662 suppressed HCC malignant progression both in vitro and in vivo. Autophagy participated in hsa_circ_0016662-regulated HCC progression via sponging with hsa-miR-22-3p.
conclusionsOur study identified hsa_circ_0016662 as a novel prognostic biomarker of HCC, promoting HCC progression by sponging with hsa-miR-22-3p via autophagy regulation. Targeting hsa_circ_0016662 might be a potential therapeutic strategy for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.